BlackRock, Inc. 13D and 13G filings for Travere Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-04-17 09:35 am Sale |
2025-03-31 | 13G | Travere Therapeutics, Inc. TVTX |
BlackRock Inc. BLK |
6,689,435 7.500% |
-1,328,857 (-16.57%) |
Filing |
| 2025-02-05 1:23 pm Purchase |
2024-12-31 | 13G | Travere Therapeutics, Inc. TVTX |
BlackRock Inc. BLK |
8,018,292 9.400% |
28,272 (+0.35%) |
Filing |
| 2024-01-24 09:46 am Purchase |
2023-12-31 | 13G | Travere Therapeutics, Inc. TVTX |
BlackRock Inc. BLK |
7,990,020 10.600% |
287,792 (+3.74%) |
Filing |
| 2023-10-06 2:34 pm Purchase |
2023-09-30 | 13G | Travere Therapeutics, Inc. TVTX |
BlackRock Inc. BLK |
7,702,228 10.300% |
2,507,443 (+48.27%) |
Filing |
| 2023-02-03 4:27 pm Purchase |
2022-12-31 | 13G | Travere Therapeutics, Inc. TVTX |
BlackRock Inc. BLK |
5,194,785 8.100% |
679,640 (+15.05%) |
Filing |
| 2022-02-02 7:18 pm Sale |
2021-12-31 | 13G | Travere Therapeutics, Inc. TVTX |
BlackRock Inc. BLK |
4,515,145 7.400% |
-310,029 (-6.43%) |
Filing |
| 2021-02-01 08:17 am Purchase |
2020-12-31 | 13G | Travere Therapeutics, Inc. TVTX |
BlackRock Inc. BLK |
4,825,174 9.500% |
4,825,174 (New Position) |
Filing |